The Patrick-Murray Administration on April 11, 2013, commended Bristol-Myers Squibb (NYSE: BMY) for its decision to invest approximately $250 million to expand the company’s large-scale biologics manufacturing facility in Devens, Massachusetts. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the company’s Massachusetts operations, while adding approximately 350 employees to the Devens workforce. The company currently has approximately 400 employees working at its Devens facility.
